Table 3.
Multivariate analysis for progression-free survival in men with non-muscle-invasive bladder tumor
| Variable | HR | 95% CI | P value |
|---|---|---|---|
| Silodosin vs. Tamsulosin | |||
| Tumor grade (high vs. low) | 12.56 | 2.314-68.14 | 0.003 |
| Tumor stage (pT1 vs. non-invasive) | 9.722 | 1.064-88.81 | 0.044 |
| α1-Blocker | 0.137 | 0.016-1.191 | 0.072 |
| Silodosin vs. Naftopidil | |||
| Tumor grade (high vs. low) | 18.85 | 1.557-228.2 | 0.021 |
| Tumor stage (pT1 vs. non-invasive) | 2.009 | 0.296-13.64 | 0.476 |
| α1-Blocker | 0.086 | 0.008-0.905 | 0.041 |
| Silodosin vs. Tamsulosin or Naftopidil | |||
| Tumor grade (high vs. low) | 12.55 | 3.082-51.07 | <0.001 |
| Tumor stage (pT1 vs. non-invasive) | 3.176 | 0.855-11.80 | 0.084 |
| α1-Blocker | 0.128 | 0.016-1.036 | 0.054 |
HR: hazard ratio; CI: confidence interval.